FRESH TRACKS THERAPEUTICS IN (FRTX) Forecast, Price Target & Analyst Ratings
NASDAQ:FRTX • US10802T2042
0.79 USD
-0.02 (-2.48%)
At close: Dec 18, 2023
0.77 USD
-0.02 (-2.53%)
After Hours: 12/18/2023, 8:00:00 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for FRESH TRACKS THERAPEUTICS IN (FRTX).
Forecast Snapshot
Consensus Price Target
$4.59
+ 481.01% Upside
Next Earnings Forecast
Release DateMar 28, 2024
PeriodQ4 / 2023
EPS Estimate-$1.54
Revenue Estimate510K
ChartMill Buy Consensus
82.86%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$4.59
Upside
+ 481.01%
From current price of $0.79 to mean target of $4.59, Based on 7 analyst forecasts
Low
$4.55
Median
$4.59
High
$4.73
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
7 Wall Street analysts provided a forecast for the next 12 months for FRTX. The average price target is 4.59 USD. This implies a price increase of 481.01% is expected in the next year compared to the current price of 0.79.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
FRTX was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about FRTX.
In the previous month the buy percentage consensus was at a similar level.
FRTX was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 28, 2024
PeriodQ4 / 2023
EPS Estimate-$1.54
Revenue Estimate510K
Revenue Q2Q-75.12%
EPS Q2Q-20.32%
Number of Analysts4
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
FRTX is expected to report earnings on 3/28/2024. The consensus EPS estimate for the next earnings is -1.54 USD and the consensus revenue estimate is 510.00K USD.
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | ||
|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.82M -77.02% | 400K -78.02% | 6.94M 1,635.00% | 3.06M -55.91% | 6.12M 100.00% | |
| EBITDA YoY % growth | -20.97M -6.77% | -40.22M -91.80% | -21.5M 46.54% | N/A | N/A | |
| EBIT YoY % growth | -20.98M -6.66% | -40.24M -91.80% | -21.53M 46.50% | -23.169M -7.61% | N/A | |
| Operating Margin | -1,152.75% | -10,060.00% | -310.23% | -757.15% | N/A | |
| EPS YoY % growth | N/A | -23.85 26.82% | N/A 68.95% | -7.00 5.44% | -6.91 1.38% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.54 -20.32% | -1.72 -2.42% | -1.86 -8.33% | -1.10 -444.25% | -2.21 -43.71% |
| Revenue Q2Q % growth | 510K -75.12% | 510K 5,000.00% | 510K 920.00% | 4.59M -42.19% | 510K |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
FRESH TRACKS THERAPEUTICS IN / FRTX Forecast FAQ
What do analysts expect the price target to be for FRESH TRACKS THERAPEUTICS IN (FRTX)?
7 analysts have analysed FRTX and the average price target is 4.59 USD. This implies a price increase of 481.01% is expected in the next year compared to the current price of 0.79.
What is the next earnings date for FRTX stock?
FRESH TRACKS THERAPEUTICS IN (FRTX) will report earnings on 2024-03-28, after the market close.
What are the consensus estimates for FRTX stock next earnings?
The consensus EPS estimate for the next earnings of FRESH TRACKS THERAPEUTICS IN (FRTX) is -1.54 USD and the consensus revenue estimate is 510.00K USD.
How do analysts rate FRESH TRACKS THERAPEUTICS IN (FRTX)?
The consensus rating for FRESH TRACKS THERAPEUTICS IN (FRTX) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.